Autoantibodies combined with systemic inflammation markers for predicting bone metastases in non-small cell lung cancer patients - Takeaways - MDSpire

Autoantibodies combined with systemic inflammation markers for predicting bone metastases in non-small cell lung cancer patients

  • By

  • Song Cheng

  • Dabin Chen

  • Rongrong Du

  • Chao Wang

  • Jiawen Xian

  • Liyuan Liu

  • Hong Wan

  • Ting Ye

  • May 26, 2026

  • 0 min

Share

  • 1

    A nomogram model was developed to predict bone metastasis risk in non-small cell lung cancer patients using autoantibodies and inflammatory markers.

  • 2

    The study analyzed data from 323 NSCLC patients, incorporating clinical, laboratory, and imaging information for model validation.

  • 3

    Seven key predictors were identified for the nomogram, including histology, TNM stage, and various autoantibodies and inflammation markers.

  • 4

    The nomogram demonstrated strong predictive ability with an AUC of 0.921 in the training cohort and 0.870 in the validation cohort.

  • 5

    Inclusion of novel biomarkers significantly enhanced the model's predictive performance, as shown by continuous NRI and IDI results.

Original Source(s)

Autoantibodies combined with systemic inflammation markers for predicting bone metastases in non-small cell lung cancer patients

  • by Song Cheng, Dabin Chen, Rongrong Du, Chao Wang, Jiawen Xian, Liyuan Liu, Hong Wan, Ting Ye

  • May 26, 2026

Related Content

Efficacy of IoT-based perioperative respiratory rehabilitation for lung resection: Protocol of a randomized controlled trial

Serum metabolomic signatures predict clinical outcomes in advanced non-small cell lung cancer treated with pembrolizumab plus platinum-based chemotherapy

Outcomes of robotic anatomic lung resection after neoadjuvant therapy for non-small cell lung cancer